Therefore, when combined with therapeutic vaccines, sunitinib may help to overcome tumor-induced immune escape leading to increased numbers of tumor-infiltrating lymphocytes and tumor-specific CD8+ T cells, as well as enhanced tumor eradication and improved survival, as was previously shown in murine models [43, 44]. Here, CD8A is linked to neoplasm.